Aligos reports positive data from Phase IIa MASH treatment trial
In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.
20 September 2024
20 September 2024
In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.